Keywords: Urinary cell mRNA profiling; Polymerase chain reaction; Rejection; Tolerance; Kidney transplantation; mRNA; messenger RNA; RT-QPCR; real-time quantitative PCR; ACR; acute cellular rejection; ROC; receiver-operating-characteristic; PI-9; proteinase inhibit
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Renal cell carcinoma; Tyrosine kinase inhibitor; PD-1; PD-L1; PD-L2;
Keywords: Lymphoid neoplasms; PD-1; PD-L1; PD-L2; Immune checkpoint;
Keywords: TME; tumour microenvironment; PD-1; programmed cell death 1; PD-L1; programmed death ligand 1; PD-L2; programmed death ligand 2; PTMs; post-translational histone modifications; DNMTi; DNA methyltransferase inhibitor; HDACi; histone deacetylase inhibitor;
Keywords: DC; dendritic cell; PD-L2; programmed cell death ligand 2; SASA; solvent-accessible surface area; FGFR2; fibroblast growth factor receptor 2; LPS; lipopolysaccharide; GST; glutathione S-transferase; PEG; polyethylene glycol; X-ray crystallography; V-set I
Keywords: 2-DG; 2-deoxy glucose; Akt; protein kinase B; ARDS; acute respiratory distress syndrome; Arg; arginase; BALF; broncho-alveolar lavage fluid; BCG; Bacillus Calmette-Guérin; CD; cluster of differentiation; cGAS; cyclic GMP-AMP synthase; COX-2; cyclooxyge
Keywords: Biomarkers; Checkpoint molecules; Cytokines; Glioblastoma; Immunotherapy; Microbiome; Mutational landscape; CB; Cintredekin besudotox; CNS; Central nervous system; CTLA-4; Cytotoxic T lymphocyte antigen 4; CyTOF; Cytometry by time-of-flight; EGFR; Epiderm
Keywords: PD-1; PD-L1; PD-L2; Lymphoid malignancies; Pidilizumab; Nivolumab; Pembrolizumab
Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma
Keywords: Renal cell carcinoma; Chromophobe; Nuclear size variation; PD-L2; Prognosis;
Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies
Keywords: ASCO; American Society of Clinical Oncology; BRAF; B-raf proto-oncogene, serine/threonine kinase; CTLA4; cytotoxic T-lymphocyte associated protein 4; ESMO; European Society for Medical Oncology; FDA; Food and Drug Administration; ICER; incremental cost-ef
microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients
Keywords: miR-125; miR-148; Antitumor Immune Response; Immune Checkpoints; CTL; cytotoxic T lymphocytes; CTLA-4; cytotoxic T lymphocyte associated protein 4; EAC; esophageal adenocarcinoma; gMFI; geometric mean fluorescence intensity; HLA-A/B/C; human leukocyte ant
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Keywords: Binimetinib (PubChem CID: 10288191); Cobimetinib (PubChem CID: 16222096); Dabrafenib (PubChem CID: 44462760); Encorafenib (PubChem CID: 50922675); Trametinib (PubChem CID: 11707110); Vemurafenib (PubChem CID: 42611257); ATC; adoptively transferred T cells
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
Keywords: PD-L1; PD-L2; Immune checkpoint; Hodgkin lymphoma; Non-Hodgkin lymphoma;
Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer
Keywords: Non-small cell lung cancer; Programmed cell death ligand 2; PD-L2; EGFR; EML4-ALK; Interferon gamma;
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
Keywords: PD-1; programmed cell death protein-1; PD-L1; programmed cell death ligand-1; PD-L2; programmed cell death ligand-2; CTLA-4; cytotoxic T-lymphocyte antigen-4; OS; overall survival; RR; response rate; HR; hazard ratio; VEGF; vascular endothelial growth fac
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Keywords: Breast cancer; Prognosis; Biomarker; Survival; PD-L1; PD-L2;
The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment
Keywords: PD-1; PD-L1; PD-L2; B7-H1; Immune checkpoint; Squamous cell carcinoma; Head and neck cancer; Immunotherapy;
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus–associated gastric carcinoma
Keywords: EBVaGC; PIK3CA; JAK2; PD-L1; PD-L2
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Keywords: PD-1; PD-L1; PD-L2; Lymphoid malignancies; Pidilizumab; Nivolumab; Pembrolizumab
Review articlePD-1/PD-L and autoimmunity: A growing relationship
Keywords: PD-1; PD-L1; PD-L2; Autoimmunity;
IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice
Keywords: MS; multiple sclerosis; EAE; experimental autoimmune encephalomyelitis; Breg; regulatory B cell; Treg; regulatory T cell; CNS; central nervous system; CDI; cumulative disease index; PD1; programmed death protein 1; PD-L; programmed death-ligand; IL-10; Re
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Keywords: PD-1; PD-L1; PD-L2; KRAS mutation; Lung cancer; Cancer immunotherapy
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Keywords: PD-1; PD-L1; PD-L2; monoclonal antibody; human cancer; immunotherapy
Human PD-1 binds differently to its human ligands: A comprehensive modeling study
Keywords: PD1; PD-L1; PD-L2; Protein-Protein docking; ZDOCK; Molecular dynamics simulations;
Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis
Keywords: Programmed death-1; Natural killer T cell; T helper-1; Effector T cells; Inteferon-gamma; APCs; antigen presenting cells; ATD; anti-tubercular drugs; Ag; antigen; Cat-I; category-I; Cat-II; category-II; HCs; healthy controls; IFN-γ; interferon gamma; IL-
Systematic validation of specific phenotypic markers for in vitro polarized human macrophages
Keywords: APC; antigen presenting cell; ATM; adipose tissue macrophage; ERK; extracellular signal-regulated kinase; FIZZ-1; found in inflammatory zone-1; GAPDH; glyceraldehyde 3-phosphate dehydrogenase; JNK; Jun N-terminal kinase; MAPK; mitogen-activated protein ki
PD-L2 is expressed on activated human T cells and regulates their function
Keywords: PD-1; programmed death 1; PD-L; programmed death 1 ligand; APCs; antigen presenting cells; TcR; T cell receptor; mAb; monoclonal antibody; T cells; Cell activation; Costimulatory molecules; PD-L2;
L2pB1: A new player in autoimmunity
Keywords: PD-L2; B1 B cells; Autoimmunity
GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes
Keywords: Tolerogenic dendritic cells; GM-CSF; Type 1 diabetes; Autoimmunity; PD-L1; PD-L2
Human iris pigment epithelial cells suppress T-cell activation via direct cell contact
Keywords: immune privilege; iris pigment epithelial cell; co-stimulatory molecule; PD-1; PD-L1; PD-L2
Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8+ T cells trigger capillary leakage in viral hemorrhagic fevers?
Keywords: Hantavirus; Endothelial cells; Cytotoxic T lymphocytes; PD-1; PD-L1; PD-L2; Hantavirus pulmonary syndrome; Hemorrhagic fever with renal syndrome
TIM-1 regulates macrophage cytokine production and B7 family member expression
Keywords: TIM-1; Macrophages; B7-H2; PD-L2; IL-6; IL-10; TNF-α
Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells
Keywords: DCs; PD-L1; PD-L2; PD-1; T-cell proliferation
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
Keywords: EAE; Multiple sclerosis; Costimulation; PD-1; PD-L1; PD-L2